Answers are grounded in this paper and cite their sources.
In 1674, Thomas Willis described diabetes mellitus (DM) due to the honey taste of a patient’s urine, thus differentiating it from diabetes insipidus (DI). Nowadays, factoring in scientific advances in the diagnosis of DM, no clinician would directly and only test a patient’s urine to diagnose said disease. In Urology, digital rectal examination (DRE) has for many years been one of the diagnostic methods in the evaluation of prostate cancer. In addition, DRE is what patients usually envision when they think about a urological consultation. Stigma associated with the DRE may even prompt patients to avoid consultation with urologists or to discuss prostate cancer screening. Specifically, the Prostate Cancer UK survey showed that 60% of men were worried about undergoing a rectal examination and that 37% of them avoided talking about symptoms related to the prostate because of concerns of a rectal examination. In addition, Black men report significantly more cultural stigma around the rectal examination but face double the risk of dying from prostate cancer.1 In recent years, the incremental contribution of DRE to PSA-based screening has been increasingly questioned for the diagnosis of prostate cancer. Indeed, an increasing number of prostate cancer screening guidelines do not mention its use. Imaging has also moved to the forefront in the evaluation of men suspected of prostate cancer. Multiparametric MRI (mpMRI) has shown value in the initial biopsy setting as highlighted by 2 sentinel randomized studies. In the PRECISION study, mpMRI demonstrated improved detection of clinically significant cancer (38 vs 26%) and lower rates of detecting nonclinically significant cancer (9 vs 22%) when compared with conventional template biopsy.2 Biparametric MRI has potential to increase study accessibility while lowering costs and study duration without compromising on outcomes.3 Collectively, DRE may play into the diagnostic realm in 3 clinical scenarios: (1) screening and early detection of prostate cancer, (2) evaluation of the local (T) stage of men with known prostate cancer, and (3) monitoring men on active surveillance for prostate cancer. Regarding screening and early detection of prostate cancer, the DRE has a published sensitivity of 28% to predict Grade Group ≥ 2 in patients with a PSA ≥ 3 ng/mL.4 The sensitivity is lower when the DRE is performed by general practitioners vs by urologists. Compared with PSA, DRE has a similar positive predictive value.5 Notably, however, the authors noted that the screening strategy of combining DRE and PSA did not differ from PSA alone regarding cancer detection (P = .5) and positive predictive value (P = .5). An argument in favor of DRE is the ability to detect aggressive, poorly differentiated tumors which are less likely to secrete high levels of PSA. In reality, these tumors account for less than 1% to 2% of patients with prostate cancer.6 Underscoring this point is the recently published PROBASE study. Here, of the 46,642 men age 45 or older, only 57 had a concerning DRE and only 3 (0.03%) were subsequently diagnosed with prostate cancer.7 Regarding local staging, DRE continues to play a role in the risk stratification of newly diagnosed prostate cancer and may inform on surgical resectability. The latter consideration is only relevant in a clinical setting where MRI is not available. In a Dutch study of 552 men treated by radical prostatectomy at 7 different centers, detection of pathologic stage ≥ T3a was greater for mpMRI compared with DRE (51% vs 12%, P < .001), whereas specificity was lower (82% vs 97%, P < .001). In addition, mpMRI resulted in a significantly higher cumulative rate of true positive and true negative stage ≥ T3a predictions compared with DRE (67% vs 58%, P < .001).8 Beyond MRI, prostate specific membrane antigen positron emission tomography (PSMA PET) can potentially add diagnostic accuracy to this scenario. In the PRIMARY study, the combination of mpMRI and PSMA PET improved diagnostic sensitivity from 83% to 97% in addition to reducing the detection rate of false negatives of clinically significant cancer from 17% to 3.1%.9 The final scenario pertains to active surveillance. Current guidelines do advocate for DRE in conjunction with PSA screening for men on an active surveillance regimen for prostate cancer. In theory, these measures would help determine the optimal timing for subsequent imaging and biopsy with progression of disease resulting in active therapy. If mpMRI is routinely obtained as part of an active surveillance regimen, then it would exceed the sensitivity of the DRE. The Movember group in its latest consensus statement suggested that when faced with the option of performing mpMRI, DRE is not necessary.10 It is important to recognize that routine use of mpMRI may incur incremental costs in an active surveillance regimen. In summary, the role of DRE in the modern day diagnosis and management of prostate cancer is limited. Screening studies highlight extremely few scenarios whereby DRE alone detects prostate cancer. Imaging has largely assumed the role of local anatomic evaluation and staging. DRE may have continued value in the realm of active surveillance particularly if the intent is to control costs associated with ubiquitous use of imaging. CONFLICT OF INTEREST None. ETHICS Not applicable.
No takes yet. Share an insight, caveat, or question.
Ferraris et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: